FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
NCT07446777 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2026-05-01
Summary
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.
Conditions
- Multiple Myeloma
- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Multiple Myeloma
Interventions
- BEHAVIORAL
-
Health Coaching
Participants will receive weekly health coaching sessions via telephone, video call, or in-person. The health coach will contact the participant after randomization to begin the intervention, which will include education on POF and following a Mediterranean diet. Sessions are expected to last 30-45 minutes and may be divided per participant preference. Participant safety and well-being will be addressed at each session, and modifications to the diet or session schedule will be made as necessary and documented. The sessions will be centrally administered by trained nutrition counselors within the Crane Lab under the supervision of a registered dietitian specializing in oncology.
- BEHAVIORAL
-
Prolonged Overnight Fasting (POF)
Participants will be instructed to not consume any calorie-containing food/drinks after 8pm and to wait 14 hours after the fasting start before resuming eating the next day. Participants will use the My Wellness Research (MWR) platform to record fasting start and stop times and times food intake daily. Additionally, workbook containing educational materials and guidance to support adherence to POF goals will be provided. In the first two weeks, participants will be encouraged to fast for at least 12 hours nightly, gradually increasing to 14 hours. Participants will aim to fast up to 14 hours overnight for six days per week, with the option of taking the seventh day off from fasting.
- BEHAVIORAL
-
Mediterranean Diet
Participants will be encouraged to adopt key components of the Mediterranean diet, including consuming 4+ vegetable servings (2.5-3 cups) daily, 2+ fruit servings (1.5-2 cups) daily, 2+ whole grain servings daily, 1+ legume serving daily, 1+ serving nuts and seeds daily, and seafood 2 times per week.
- BEHAVIORAL
-
Supportive Materials
Participants in the intervention arm will be provided with a workbook with information and support to encourage meeting the POF and Mediterranean diet goals. Additionally, participants will be requested to utilize the My Wellness Research (MWR) platform to track their dietary goals as well as a Fitbit. For participants who choose not to use the app, a paper diet tracking sheet will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to the research team each week. Participants will also receive supportive and informational short message service (SMS) text messages 3 times per week during the study; participants can opt-out of these messages.
Sponsors & Collaborators
-
University of Miami
lead OTHER
Principal Investigators
-
Tracy E Crane, PhD, RDN · University of Miami
-
Carl O Landgren, MD · University of Miami
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-07
- Primary Completion
- 2029-04-30
- Completion
- 2029-04-30
Countries
- United States
Study Locations
More Related Trials
-
Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
NCT02703779 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT03650491 ·Status: COMPLETED ·Phase: PHASE1
-
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
NCT00691704 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
NCT01965834 ·Status: TERMINATED ·Phase: PHASE2
-
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
NCT00900263 ·Status: COMPLETED
-
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
NCT04960579 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
NCT05361694 ·Status: RECRUITING
-
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
NCT01054144 ·Status: COMPLETED ·Phase: PHASE2
-
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07032714 ·Status: RECRUITING ·Phase: PHASE1
-
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
NCT05686447 ·Status: RECRUITING
-
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)
NCT02576977 ·Status: TERMINATED ·Phase: PHASE3
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
NCT01208766 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
NCT06149910 ·Status: RECRUITING
-
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
NCT04497961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)
NCT05276622 ·Status: TERMINATED
-
Sleep Apnea in Patients With MGUS and MM
NCT04114084 ·Status: RECRUITING
-
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
NCT01783522 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
NCT05742217 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02561962 ·Status: COMPLETED ·Phase: PHASE1
-
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00477750 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Non-invasive MRD Assessment in Multiple Myeloma
NCT05625971 ·Status: COMPLETED
-
Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma
NCT03119883 ·Status: COMPLETED ·Phase: NA
-
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
NCT00747877 ·Status: UNKNOWN ·Phase: PHASE3